{"id":"NCT00525265","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)","officialTitle":"A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2009-01","completion":"2009-01","firstPosted":"2007-09-05","resultsPosted":"2013-12-25","lastUpdate":"2013-12-25"},"enrollment":20,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cardiac Edema"],"interventions":[{"type":"DRUG","name":"OPC-41061(Tolvaptan)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"To investigate the pharmacokinetics, pharmacodynamics (urine volume and fluid intake), efficacy(body weight, pulmonary congestion and other congestions including cardiothoracic ratio) and safety of 7-day repeated oral administration of OPC-41061 at 7.5 mg or 15 mg in congestive heart failure (cardiac edema) patients with extracellular volume expansion despite the use of a diuretic.","primaryOutcome":{"measure":"Body Weight","timeFrame":"Baseline, at the time of final trial drug administration","effectByArm":[{"arm":"OPC-41061 7.5 mg","deltaMin":-1.68,"sd":1.83},{"arm":"OPC-41061 15 mg","deltaMin":-2.14,"sd":1.45}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":2,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":10},"commonTop":["Thirst","Blood Urea Increased","Blood Creatinine Increased","Pyrexia","Pollakiuria"]}}